Abstract
To study the potential interaction between carbamazepine (CBZ) and selective serotonin reuptake inhibitors, fluoxetine (20 mg/day) and fluvoxamine (100 mg/day) were administered for 3 weeks to eight and seven epileptic patients, respectively, on chronic CBZ treatment. No significant changes in steady-state plasma concentrations of CBZ and its active metabolite, carbamazepine-10,11-epoxide (CBZ-E) occurred, suggesting that CBZ metabolism is probably not affected by fluoxetine or fluvoxamine administration.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Carbamazepine / analogs & derivatives
-
Carbamazepine / blood*
-
Carbamazepine / therapeutic use*
-
Depression / blood
-
Depression / complications
-
Depression / drug therapy
-
Drug Interactions
-
Drug Therapy, Combination
-
Epilepsy, Complex Partial / blood
-
Epilepsy, Complex Partial / complications
-
Epilepsy, Complex Partial / drug therapy
-
Epilepsy, Tonic-Clonic / blood
-
Epilepsy, Tonic-Clonic / drug therapy
-
Female
-
Fluoxetine / therapeutic use*
-
Fluvoxamine / therapeutic use*
-
Humans
-
Male
-
Middle Aged
Substances
-
Fluoxetine
-
Carbamazepine
-
Fluvoxamine
-
carbamazepine epoxide